Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to $122.4 million.

  • Solid Biosciences' Cash from Financing Activities rose 1274.26% to $6.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.4 million, marking a year-over-year increase of 62.57%. This contributed to the annual value of $122.4 million for FY2024, which is 3821.75% up from last year.
  • Per Solid Biosciences' latest filing, its Cash from Financing Activities stood at $122.4 million for FY2024, which was up 3,821.75% from $3.1 million recorded in FY2023.
  • Solid Biosciences' Cash from Financing Activities' 5-year high stood at $135.0 million during FY2021, with a 5-year trough of $3.1 million in FY2023.
  • Over the past 3 years, Solid Biosciences' median Cash from Financing Activities value was $74.8 million (recorded in 2022), while the average stood at $66.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 95.83% in 2023, then surged by 3,821.75% in 2024.
  • Solid Biosciences' Cash from Financing Activities (Yearly) stood at $128.7 million in 2020, then grew by 4.88% to $135.0 million in 2021, then slumped by 44.56% to $74.8 million in 2022, then crashed by 95.83% to $3.1 million in 2023, then surged by 3,821.75% to $122.4 million in 2024.